Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 8Withdrawn 1Unknown 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 41Lymphoid 10Other hematologic neoplasm 6Thoracic 2Gastrointestinal 2CNS 2Other solid neoplasm 1Gynecologic 1Genitourinary 1

Conditions

Ovarian Neoplasm Epithelial 1

Interventions

Paclitaxel 79Cisplatin 72Carboplatin 72Bevacizumab 29Radiotherapy 27Brachytherapy 23Hyperthermic Intraperitoneal Chemotherapy 20Drug Therapy 20olaparib 19Gemcitabine 17niraparib 16apatinib 16pembrolizumab 15Surgical Procedures, Operative 15liposomal doxorubicin 12Cyclophosphamide 12Surveys and Questionnaires 11camrelizumab 10Taxes 10Neoadjuvant Therapy 10fludarabine 9anlotinib 9Etoposide 9Blood Specimen Collection 9Topotecan 8Docetaxel 8Sentinel Lymph Node Biopsy 7Platinum 7Injections 7Cytoreduction Surgical Procedures 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Bortezomib × Gynecologic × Clear all
NCT03509246 2020-01-14

Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Patients

Seoul National University Hospital

Phase 2 Unknown
44 enrolled
Gynecologic

Ovarian Neoplasm Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡